- Home
- CRVS vs DBI Comparison
CRVS vs DBI Comparison
Compare CRVS & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- DBI
- Stock Information
- Founded
- CRVS 2014
- DBI 1991
- Country
- CRVS United States
- DBI United States
- Employees
- CRVS N/A
- DBI N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- CRVS Health Care
- DBI Consumer Discretionary
- Exchange
- CRVS Nasdaq
- DBI Nasdaq
- Market Cap
- CRVS 206.5M
- DBI 222.4M
- IPO Year
- CRVS 2016
- DBI 1991
- Fundamental
- Price
- CRVS $3.63
- DBI $2.75
- Analyst Decision
- CRVS Strong Buy
- DBI Hold
- Analyst Count
- CRVS 3
- DBI 2
- Target Price
- CRVS $15.67
- DBI $4.75
- AVG Volume (30 Days)
- CRVS 906.6K
- DBI 2.0M
- Earning Date
- CRVS 05-05-2025
- DBI 06-03-2025
- Dividend Yield
- CRVS N/A
- DBI 7.25%
- EPS Growth
- CRVS N/A
- DBI N/A
- EPS
- CRVS N/A
- DBI N/A
- Revenue
- CRVS N/A
- DBI $3,009,262,000.00
- Revenue This Year
- CRVS N/A
- DBI $2.22
- Revenue Next Year
- CRVS N/A
- DBI $2.18
- P/E Ratio
- CRVS N/A
- DBI N/A
- Revenue Growth
- CRVS N/A
- DBI N/A
- 52 Week Low
- CRVS $1.43
- DBI $2.45
- 52 Week High
- CRVS $10.00
- DBI $11.06
- Technical
- Relative Strength Index (RSI)
- CRVS 55.04
- DBI 39.39
- Support Level
- CRVS $3.15
- DBI $2.44
- Resistance Level
- CRVS $3.78
- DBI $2.89
- Average True Range (ATR)
- CRVS 0.25
- DBI 0.28
- MACD
- CRVS 0.12
- DBI 0.03
- Stochastic Oscillator
- CRVS 87.90
- DBI 38.75
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.